Table 2.
Patienta | C3(0.68–1.38 g/l) | C4 (0.18–0.6 g/l) | CD46 | FH (0.35–0.59 g/l) | FI (38–58 mg/l) |
---|---|---|---|---|---|
2 | 0.57 | 0.15 | Not tested | 0.44 | 70 |
4b | 0.89 | 0.3 | Normal | 0.52 | 41 |
5b | 0.92 | 0.2 | Not tested | 0.29 | Not tested |
6b | 1.08 | 0.36 | Not tested | 0.5 | 74 |
10 | 1.06 | 0.13 | Not tested | 0.45 | 68 |
12b | 1.02 | 0.19 | Normal | 0.57 | 62 |
14 | 0.65 | 0.31 | Normal | 0.43 | 41 |
15 | 0.77 | 0.29 | Normal | 0.23 | 84 |
16 | 0.95 | 0.51 | Normal | 0.53 | 42 |
17 | 1.06 | 0.24 | Normal | 0.53 | 44 |
18 | 1.1 | 0.18 | Normal | 0.48 | 52 |
19b | 1.23 | 0.52 | Normal | 0.48 | 70 |
20 | 0.51 | 0.16 | Not tested | 0.48 | 59 |
21 | 1.61 | 0.29 | Normal | 0.77 | 73 |
22b | 1.22 | 0.2 | Normal | 0.73 | 78 |
23 | 0.91 | 0.16 | Not tested | 0.39 | 65 |
24 | 0.61 | 0.14 | Normal | 0.51 | 62 |
FH, factor H; FI, factor I.
Identification numbers for patients 2, 4, 5, 6, 10, and 12 correspond to those in a previous publication.9
Indicates patients in whom established renal failure developed.